Pierre Kemula
Director of Finance/CFO at CUREVAC N.V.
Net worth: 219 175 $ as of 31/03/2024
Profile
Mr. Pierre Kemula is a Chief Financial Officer at CureVac NV and a Chief Financial Officer at CureVac AG. Mr. Kemula was previously employed as a Chief Financial Officer by Pixium Vision SA and a VP-Treasury, Financial Markets & Corporate Finance by Ipsen SA. He received his undergraduate degree from London School of Economics & Political Science.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CUREVAC N.V.
0.03% | 31/03/2023 | 72,335 ( 0.03% ) | 219 175 $ | 31/03/2024 |
Pierre Kemula active positions
| Companies | Position | Start |
|---|---|---|
| CUREVAC N.V. | Director of Finance/CFO | 01/11/2016 |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Director of Finance/CFO | 01/01/2016 |
Former positions of Pierre Kemula
| Companies | Position | End |
|---|---|---|
| PIXIUM VISION | Director of Finance/CFO | 16/02/2017 |
| IPSEN | Public Communications Contact | 01/01/2014 |
Training of Pierre Kemula
| London School of Economics & Political Science | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| IPSEN | Health Technology |
| PIXIUM VISION | Health Technology |
| CUREVAC N.V. | Health Technology |
| Private companies | 1 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
- Stock Market
- Insiders
- Pierre Kemula
